Filter posts

CMS’s Own Data Do NOT Support Claims on Part B Drug Spending

In a story entitled, “CMS Blames Medicare Part B Hikes on Drug Costs,” writers for …

Expanding Benefits to Members, BIO Now Offering Education and Training Courses

BIO is continually looking for ways to help its members grow and prosper. This week …

The Pelosi Plan and "Me Too" Drugs

Supporters of Speaker Pelosi’s drug pricing plan (H.R. 3) claim the bill will discourage the …

Fundraising Companies Find Strategic Partners that Best Fit Their Stage of Development at BIO Invest...

Since its inception 17 years ago, the BIO Investor Forum has become the premier event …

New BIO One-on-One Partnering Mobile App

BIO has released a new and improved mobile app for the BIO One-on-One Partnering™ system. …

BIO's Leadership Transition | "The fight continues..."

On Tuesday, October 8, BIO formally announced that its President and CEO Jim Greenwood would …

Pitch Perfect – Storytelling is Key for BIO One-on-One Partnering

Keith Ignotz knows the power of a good story. The President & CEO of OcuMedic—an early …

The Strong Keep Getting Stronger: Why the Bay Area Remains #1 Biotech Hub for VC Investing

Whether you come to the Bay Area for the entrepreneurial talent, venture capital investment or …

The BIO Investor Forum Links Promising Early-Stage Technologies with an Active Investor Network

As the biopharma industry has gained traction on new drug approvals throughout 2019, the financial …

Influential investor, Wende Hutton, to Speak at #BIF19

In a few short months BIO will be hosting the BIO Investor Forum (#BIF19) for …